TD Cowen downgraded Aerovate Therapeutics to Hold from Buy after the company’s AV-101 failed to show statistically significant or clinically meaningful results on the primary endpoint or several important secondary endpoints in the Phase 2b portion of the IMPAHCT trial in pulmonary arterial hypertension, or PAH.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTE:
- Aerovate Therapeutics Halts Studies Amid Phase 2b Setback
- Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
- Aerovate Therapeutics files $350M mixed securities shelf
- Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
- Aerovate Therapeutics reports Q1 EPS (83c), consensus (76c)